Triple-Negative Breast Cancer: Global Clinical Trial Landscape (2024)

Triple-negative breast cancer (TNBC) is a highly aggressive subtype, characterized by the absence of ER, PR, and HER2 expression, TNBC has limited targeted treatment options, leading to poor prognoses. The evolving treatment landscape integrates biomarker-driven strategies, including immune checkpoint inhibitors (e.g., pembrolizumab), antibody-drug conjugates (e.g., sacituzumab govitecan), and PARP inhibitors for BRCA-mutated cases.

With over 1,500 TNBC-focused clinical trials since 2019, research efforts are accelerating, particularly in North America and Asia-Pacific. Emerging therapies such as datopotamab deruxtecan and novel combination regimens offer promising advancements. Precision medicine approaches leverage biomarkers like PD-L1 expression and PI3K/AKT alterations to refine therapeutic strategies. Despite challenges such as drug resistance, ongoing innovation drives progress. Novotech, a leading clinical research organization, supports over 5,000 clinical projects globally and is pivotal in shaping the future of TNBC research and treatment through immuno-oncology and targeted therapy trials.